New Cancer Target Identified for Albumin Enabled Anti-Cancer Therapeutics

AARHUS, DENMARK - Jun 26, 2018 - Aarhus University's Interdisciplinary Nanoscience Center (iNANO) and Albumedix Ltd. (‘Albumedix’) have entered into a strategic research collaboration to evaluate the transport properties of albumin for site-selective drug delivery into disease cells to ensure more efficient and safer treatment for patients. Researchers from the NanoPharmaceutical Lab at Aarhus University’s Interdisciplinary Nanoscience Center (iNANO), led by Associate Professor Ken Howard, together with Researchers from Albumedix Ltd., have identified a novel target in several cancer types that may pave the way for efficient delivery of drugs into cancer cells using the blood protein albumin as a carrier.

Today, a major leap towards this goal has been taken with the publication of a joint patent application (Identification and treatment of tumors characterized by an overexpression of the neonatal Fc receptor) between iNANO and Albumedix, that describes the overexpression of an albumin binding receptor in several cancer types providing a novel target for site-selective drug delivery. Identification of the over production of the neonatal Fc receptor (FcRn) in a broad range of cancer types screened from ~500 cancer patient biopsies is a groundbreaking result that is the basis for the published patent application.

Albumin is a blood protein that has a predominant role in the transport of nutrient molecules required for healthy cell growth. Its functions are facilitated by its long residence time in the blood due to engagement with the cellular recycling FcRn. The overzealous requirement of cancer cells for nutrients prompted the team to investigate whether over production of FcRn occurs in tumors as a method to quench the nutrient thirst that could also explain previously reported albumin accumulation in tumors in the literature.

“This is exciting work. It offers potential for site-selective targeting of drugs to cancer cells, thus overcoming a major hurdle in cancer therapeutics,” commented Associate Professor Ken Howard (Aarhus University). “The invention is based on sound scientific rationale and biological understanding that was executed through our long-standing relationship with Albumedix, facilitated by generous support from Innovation Fund Denmark. Harnessing the transport properties of a natural protein rather than relying on complicated drug delivery designs potentially offers a shorter path to clinic. Focus now is on incorporation of anti-cancer drugs into the albumins achieved through continued strong interaction and collaboration with Albumedix Ltd.”

Albumedix’ engineered recombinant albumins (Veltis®), specifically designed with an unprecedented high affinity towards the identified receptor, has been shown to exhibit greater accumulation in tumors implanted in mice. This offers a potential strategy for site-specific delivery of cancer drugs without toxic side effects associated with conventional anti-cancer medicines.

Jason Cameron, Science Director at Albumedix, commented: “Our great and long collaboration with Ken Howard and his group at iNANO, facilitated by the DKK nine million grant from the Innovation Fund Denmark, has moved us closer to better understanding the full potential of our engineered albumins in the fight against cancer - a fight where albumin-enabled therapeutics might provide an alternative treatment approach,” said

Notes to Editors:

About Veltis:

Veltis is a unique drug delivery technology platform based around Albumedix’ engineered human albumin variants. The technology offers great potential for the development of novel therapies with tailored delivery and improved therapeutic performance. Based on ground-breaking science, Veltis displays an unprecedented affinity for albumin’s natural receptor, the Neonatal Fc Receptor (FcRn); opening the possibility for monthly dosing as well as novel delivery and targeting mechanisms.  Furthermore, the introduction of several additional drug attachment sites offers the possibility for specificity and increased payload capacity.

About Albumedix

Albumedix is a science-driven, biotechnology company focused on developing superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. Dedicated to Better Health, we partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin and are as passionate about albumin-enabled therapeutics as we were when we started 30 years ago. Headquartered in Nottingham, United Kingdom, we are more than 80 people, all committed to improving patient quality of life.

About iNANO

The Interdisciplinary Nanoscience Center (iNANO), is an internationally leading nanoscience center at Aarhus University, which is the largest public university in Denmark. iNANO fosters excellent interdisciplinary research and education within the area of nanoscience and nanotechnology. It provides a framework in which leading-edge expertise in physics, chemistry, molecular biology, biology, engineering and medicine are combined to create an interdisciplinary environment of international stature with regards to science and technology, and a regional and national power hub for enhancing industrial competitiveness.

Patent title: “Identification and treatment of tumors characterized by an overexpression of the neonatal Fc receptor”

Patent number: WO2018/082758

Inventors: Kenneth Alan Howard (AU, iNANO), Jason Cameron (Albumedix Ltd.), Maja Thim Larsen (AU, iNANO), Frederik Dagnæs-Hansen (AU, Department of Biomedicine)

For further information, please visit www.albumedix.com